Progress toward the genetic treatment of the β-thalassemias

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 78-91

  Sadelain, Michel ^a   Lisowski, Leszek ^a   Samakoglu, Selda ^a   Rivella, Stefano ^a   May, Chad ^a   Riviere, Isabelle ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hematopoietic stem cell; Lentiviral vector; Thalassemia; globin

Indexed keywords

BETA GLOBIN; GAMMA GLOBIN; HEMOGLOBIN; LENTIVIRUS VECTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; BETA THALASSEMIA; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL SPECIFICITY; CONFERENCE PAPER; DRUG SAFETY; ERYTHROID CELL; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; NONHUMAN; ONCOGENE; RISK ASSESSMENT; STEM CELL GENE THERAPY; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS GENOME;

LENTIVIRUS;

EID: 29744467396     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.010     Document Type: Conference Paper

References (97)

1. WEATHERALL, D.J. & J.B. CLEGG. 1981. The Thalassemia Syndrome. Blackwell Scientific. Oxford.
2. STAMATOYANNOPOULOS, G., A.W. NIENHUIS, P. MAJERUS & H. VARMUS. 1994. The Molecular Basis of Blood Diseases. Saunders. Philadelphia.
3. WEATHERALL, D.J. 2001. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat. Rev. Genet. 2: 245-255.
4. STEINBERG, M.H., B.G. FORGET, D.R. HIGGS & R.L. NAGEL. 2001. Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. Cambridge University Press. Cambridge, UK.
5. COOLEY, T.B. & P.A. LEE. 1925. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans. Am. Pediatr. Soc. 37: 29.
6. GIARDINA, P.J. & R.W. GRADY. 2001. Chelation therapy in beta-thalassemia: an optimistic update. Semin. Hematol. 38: 360-366.
7. GIARDINI, C. & G. LUCARELLI. 1994. Bone marrow transplantation in the treatment of thalassemia. Curr. Opin. Hematol. 1: 170-176.
8. BOULAD, F., P. GIARDINA, A. GILLIO, et al. 1998. Bone marrow transplantation for homozygous beta-thalassemia. The Memorial Sloan-Kettering Cancer Center experience. Ann. N.Y. Acad. Sci. 850: 498-502.
9. LUCARELLI, G., R.A. CLIFT, M. GALIMBERTI, et al. 1999. Bone marrow transplantation in adult thalassemic patients. Blood 93: 1164-1177.
10. TISDALE, J. & M. SADELAIN. 2001. Toward gene therapy for disorders of globin synthesis. Semin. Hematol. 38: 382-392.
11. STEINBERG, M.H., B.G. FORGET, D.R. HIGGS & R.L. NAGEL. 2001. Molecular Mechanism of β Thalassemia. Cambridge University Press. Cambridge, UK.
12. PAULING, L., H.A. ITANO, S.J. SINGER & I.C. WELLS. 1949. Sickle cell anemia, a molecular disease. Science 110: 543-546.
13. SWANK, R.A. & G. STAMATOYANNOPOULOS. 1998. Fetal gene reactivation. Curr. Opin. Genet. Dev. 8: 366-370.
14. PLATT, O.S., S.H. ORKIN, G. DOVER, et al. 1984. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J. Clin. Invest. 74: 652-656.
15. CHARACHE, S., G.J. DOVER, R.D. MOORE, et al. 1992. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79: 2555-2565.
16. ATWEH, G.F. & D. LOUKOPOULOS. 2001. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin. Hematol. 38: 367-373.
17. VERMYLEN, C., G. CORNU, A. FERSTER, et al. 1998. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 22: 1-6.
18. LUZZATTO, L. & P. GOODFELLOW. 1989. Sickle cell anaemia. A simple disease with no cure. Nature 337: 17-18.
19. SADELAIN, M. 1997. Genetic treatment of the haemoglobinopathies: recombinations and new combinations. Br. J. Haematol. 98: 247-253.
20. LEBOULCH, P., G.M. HUANG, R.K. HUMPHRIES, et al. 1994. Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. EMBO J. 13: 3065-3076.
21. SADELAIN, M., C.H. WANG, M. ANTONIOU, et al. 1995. Generation of a high-liter retroviral vector capable of expressing high levels of the human beta-globin gene. Proc. Natl. Acad. Sci. USA 92: 6728-6732.
22. MAY, C., S. RIVELLA, J. CALLEGARI, et al. 2000. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406: 82-86.
23. CONE, R.D., A. WEBER-BENAROUS, D. BAORTO & R.C. MULLIGAN. 1987. Regulated expression of a complete human beta-globin gene encoded by a transmissible retrovirus vector. Mol. Cell. Biol. 7: 887-897.
24. KARLSSON, S., T. PAPAYANNOPOULOU, S.G. SCHWEIGER, et al. 1987. Retroviral-mediated transfer of genomic globin genes leads to regulated production of RNA and protein. Proc. Natl. Acad. Sci. USA 84: 2411-2415.
25. DZIERZAK, E.A., T. PAPAYANNOPOULOU & R.C. MULLIGAN. 1988. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 331: 35-41.
26. BENDER, M.A., R.E. GELINAS & A.D. MILLER. 1989. A majority of mice show long-term expression of a human beta-globin gene after retrovirus transfer into hematopoietic stem cells. Mol. Cell. Biol. 9: 1426-1434.
27. BODINE, D.M., S. KARLSSON & A.W. NIENHUIS. 1989. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 86: 8897-8901.
28. PLAVEC, I., T. PAPAYANNOPOULOU, C. MAURY & F. MEYER. 1993. A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood 81: 1384-1392.
29. CHANG, J.C., D. LIU & Y.W. KAN. 1992. A 36-base-pair core sequence of locus control region enhances retrovirally transferred human beta-globin gene expression. Proc. Natl. Acad. Sci. USA 89: 3107-3110.
30. NOVAK, U., E.A. HARRIS, W. FORRESTER, et al. 1990. High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells. Proc. Natl. Acad. Sci. USA 87: 3386-3390.
31. HIGGS, D.R. 1998. Do LCRs open chromatin domains? Cell 95: 299-302.
32. BULGER, M. & M. GROUDINE. 1999. Looping versus linking: toward a model for long-distance gene activation. Genes Dev. 13: 2465-2477.
33. GROSVELD, F. 1999. Activation by locus control regions? Curr. Opin. Genet. Dev. 9: 152-157.
34. ENGEL, J.D. & K. TANIMOTO. 2000. Looping, linking, and chromatin activity: new insights into beta-globin locus regulation. Cell 100: 499-502.
35. NAVAS, P.A., Q. LI, K.R. PETERSON, et al. 2002. Activation of the beta-like globin genes in transgenic mice is dependent on the presence of the beta-locus control region. Hum. Mol. Genet. 11: 893-903.
36. DE KROM, M., M. VAN DE CORPUT, M. VON LINDERN, et al. 2002. Stochastic patterns in globin gene expression are established prior to transcriptional activation and are clonally inherited. Mol. Cell 9: 1319-1326.
37. BULGER, M., T. SAWADO, D. SCHUBELER & M. GROUDINE. 2002. ChIPs of the beta-globin locus: unraveling gene regulation within an active domain. Curr. Opin. Genet. Dev. 12: 170-177.
38. LEVINGS, P.P. & J. BUNGERT. 2002. The human beta-globin locus control region. Eur. J. Biochem. 269: 1589-1599.
39. RIVELLA, S., L. LISOWSKI & M. SADELAIN. 2003. Globin gene transfer: a paradigm for transgene regulation and vector safety. Gene Ther. Reg. 2: 149-175.
40. ELLIS, J., P. PASCERI, K.C. TAN-UN, et al. 1997. Evaluation of beta-globin gene therapy constructs in single copy transgenic mice. Nucleic Acids Res. 25: 1296-1302.
41. REN, S., B.Y. WONG, J. LI, et al. 1996. Production of genetically stable high-liter retroviral vectors that carry a human gamma-globin gene under the control of the alpha-globin locus control region. Blood 87: 2518-2524.
42. LUNG, H.Y., I.S. MEEUS, R.S. WEINBERG & G.F. ATWEH. 2000. In vivo silencing of the human gamma-globin gene in murine erythroid cells following retroviral transduction. Blood Cells Mol. Dis. 26: 613-619.
43. EMERY, D.W., F. MORRISH, Q. LI & G. STAMATOYANNOPOULOS. 1999. Analysis of gamma-globin expression cassettes in retrovirus vectors. Hum. Gene Ther. 10: 877-888.
44. SABATINO, D.E., C. WONG, A.P. CLINE, et al. 2000. A minimal ankyrin promoter linked to a human gamma-globin gene demonstrates erythroid specific copy number dependent expression with minimal position or enhancer dependence in transgenic mice. J. Biol. Chem. 275: 28549-28554.
45. SABATINO, D.E., N.E. SEIDEL, G.J. AVILES-MENDOZA, et al. 2000. Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter. Proc. Natl. Acad. Sci. USA 97: 13294-13299.
46. EMERY, D.W., E. YANNAKI, J. TUBB, et al. 2002. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 100: 2012-2019.
47. FRAGKOS, M., et al. 2005. Use of the hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human gamma-globin. Gene Ther. In press.
48. KALBERER, C.P., R. PAWLIUK, S. IMREN, et al. 2000. Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human β-globin in engrafted mice. Proc. Natl. Acad. Sci. USA 97: 5411-5415.
49. NICOLINI, F.E., S. IMREN, I.H. OH, et al. 2002. Expression of a human beta-globin transgene in erythroid cells derived from retrovirally transduced transplantable human fetal liver and cord blood cells. Blood 100: 1257-1264.
50. SALMON, P. & D. TRONO. 2002. Lentiviral vectors for the gene therapy of lymphohematological disorders. Curr. Top. Microbiol. Immunol. 261: 211-227.
51. FOLLENZI, A. & L. NALDINI. 2002. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 346: 454-465.
52. LEWIS, P.F. & M. EMERMAN. 1994. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68: 510-556.
53. GOFF, S.P. 2001. Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. J. Gene Med. 3: 517-528.
54. FISCHER, U., J. HUBER, W.C. BOELENS, et al. 1995. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82: 475-483.
55. WEN, W., J.L. MEINKOTH, R.Y. TSIEN & S.S. TAYLOR. 1995. Identification of a signal for rapid export of proteins from the nucleus. Cell 82: 463-473.
56. FORNEROD, M., M. OHNO, M. YOSHIDA & I.W. MATTAJ. 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90: 1051-1060.
57. YI, R., H.P. BOGERD, H.L. WIEGAND & B.R. CULLEN. 2002. Both ran and importins have the ability to function as nuclear mRNA export factors. RNA 8: 180-187.
58. YI, R., H.P. BOGERD & B.R. CULLEN. 2002. Recruitment of the Crm1 nuclear export factor is sufficient to induce cytoplasmic expression of incompletely spliced human immunodeficiency virus mRNAs. J. Virol. 76: 2036-2042.
59. MIYOSHI, H., U. BLOMER, M. TAKAHASHI, et al. 1998. Development of a self-inactivating lentivirus vector. J. Virol. 72: 8150-8157.
60. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283: 682-686.
61. - bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol. Ther. 1: 566-573.
62. MANGEOT, P.E., K. DUPERRIER, D. NEGRE, et al. 2002. High levels of transduction of human dendritic cells with optimized SIV vectors. Mol. Ther. 5: 283-290.
63. FOLLENZI, A., G. SABATINO, A. LOMBARDO, et al. 2002. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13: 243-260.
64. DYALL, J., J.B. LATOUCHE, S. SCHNELL & M. SADELAIN. 2001. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97: 114-121.
65. PIACIBELLO, W., S. BRUNO, F. SANAVIO, et al. 2002. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Blood 100: 4391-4400.
66. SUTTON, R.E., M.J. REITSMA, N. UCHIDA & P.O. BROWN. 1999. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J. Virol. 73: 3649-3660.
67. SADELAIN, M., F. FRASSONI & I. RIVIERE. 2000. Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. Curr. Opin. Hematol. 7: 364-377.
68. KUMAR, M., B. KELLER, N. MAKALOU & R.E. SUTTON. 2001. Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. 12: 1893-1905.
69. WU, X., Y. LI, B. CRISE & S.M. BURGESS. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
70. MITCHELL, R.S., B.F. BEITZEL, A.R. SCHRODER, et al. 2004. Retroviral DNA integration: ASLV, HIV and MLV show distinct target site preferences. PLoS Biol 2: E234.
71. MALIM, M.H., J. HAUBER, S.Y. LE, et al. 1989. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338: 254-257.
72. RIVELLA, S., C. MAY, A. CHADBURN, et al. 2003. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 101: 2932-2939.
73. PAWLIUK, R., K.A. WESTERMAN, M.E. FABRY, et al. 2001. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371.
74. NAGEL, R.L., R.M. BOOKCHIN, J. JOHNSON, et al. 1979. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc. Natl. Acad. Sci. USA 76: 670-672.
75. LEVASSEUR, D.N., T.M. RYAN, K.M. PAWLIK & T.M. TOWNES. 2003. Correction of a mouse model of sickle cell disease: lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102: 4312-4319.
76. PERSONS, D.A., P.W. HARGROVE, E.R. ALLAY, et al. 2002. The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human γ-globin gene is influenced by chromosomal position effects and vector copy number. Blood 101: 2175-2183.
77. RIVELLA, S. & M. SADELAIN. 2002. Therapeutic globin gene delivery using lentiviral vectors. Curr. Opin. Mol. Ther. 4: 505-514.
78. MAY, C., S. RIVELLA, A. CHADBURN & M. SADELAIN. 2002. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 99: 1902-1908.
79. TRUDEL, M., M.E. DE PAEPE, N. CHRETIEN, et al. 1994. Sickle cell disease of transgenic SAD mice. Blood 84: 3189-3197.
80. PASZTY, C., C.M. BRION, E. MANCI, et al. 1997. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278: 876-878.
81. IMREN, S., E. PAYEN, K.A. WESTERMAN, et al. 2002. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 99: 14380-14385.
82. KOHN, D.B. 2001. Gene therapy for genetic haematological disorders and immunodeficiencies. J. Intern Med. 249: 379-390.
83. ROSENBERG, N., et al. 1997. In Retroviruses. A.M. Coffin, S.H. Hughes & H.E.Varmus, Eds: 475-585. Cold Spring Harbor Laboratory Press. New York.
84. BERNS MIKKERS, H., J. ALLEN, P. KNIPSCHEER, et al. 2002. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat. Genet. 32: 153-159.
85. SUZUKI, T., H. SHEN, K. AKAGI, et al. 2002. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 32: 166-174.
86. BAUM, C., J. DULLMANN, Z. LI, et al. 2003. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101: 2099-2114.
87. KOHN, D.B., M. SADELAIN, C. DUNBAR, et al. 2003. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol. Ther. 8: 180-187.
88. LI, Z., J. DULLMANN, B. SCHIEDLMEIER, et al. 2002. Murine leukemia induced by retroviral gene marking. Science 296: 497.
89. HACEIN-BEY-ABINA, S., C. VON KALLE, M. SCHMIDT, et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
90. KOHN, D.B., M. SADELAIN & J.C. GLORIOSO. 2003. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer 3: 477-488.
91. DAVE, U.P., N.A. JENKINS & N.G. COPELAND. 2004. Gene therapy insertional mutagenesis insights. Science 303: 333.
92. SADELAIN, M. 2004. Insertional oncogenesis in human gene therapy: how much of a risk? Gene Ther. 11: 569-573.
93. RIVELLA, S., J.A. CALLEGARI, C. MAY, et al. 2000. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. Virol. 74: 4679-4687.
94. EMERY, D.W., E. YANNAKI, J. TUBB & G. STAMATOYANNOPOULOS. 2000. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc. Natl. Acad. Sci. USA 97: 9150-9155.
95. YANNAKI, E., J. TUBE, M. AKER, et al. 2002. Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Mol. Ther. 5: 589-598.
96. PUTHENVEETIL, G., J. SCHOLES, D. CARBONELL, et al. 2004. Successful correction of human β-thalassemia major phenotype using a lentiviral vector. Blood 104: 3445-3453.
97. ZUFFEREY, R., D. NAGY, R.J. MANDEL, et al. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15: 871-875.